@article{discovery10184137,
           month = {April},
          number = {7},
         journal = {JCI Insight},
       publisher = {American Society for Clinical Investigation},
            year = {2022},
           title = {Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV},
            note = {Copyright: {\copyright} 2022, Ogbe et al. This is an open access article published under the terms of the Creative CommonsAttribution 4.0 International License.},
          volume = {7},
        keywords = {AIDS/HIV, Adaptive immunity, COVID-19, Cellular immune response, T cells, COVID-19, ChAdOx1 nCoV-19, HIV Infections, Humans, Male, SARS-CoV-2, Vaccination},
        abstract = {Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells {\ensuremath{>}} 350 cells/{\ensuremath{\mu}}L) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-{\ensuremath{\gamma}} ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.},
            issn = {2379-3708},
          author = {Ogbe, A and Pace, M and Bittaye, M and Tipoe, T and Adele, S and Alagaratnam, J and Aley, PK and Ansari, MA and Bara, A and Broadhead, S and Brown, A and Brown, H and Cappuccini, F and Cinardo, P and Dejnirattisai, W and Ewer, KJ and Fok, H and Folegatti, PM and Fowler, J and Godfrey, L and Goodman, AL and Jackson, B and Jenkin, D and Jones, M and Longet, S and Makinson, RA and Marchevsky, NG and Mathew, M and Mazzella, A and Mujadidi, YF and Parolini, L and Petersen, C and Plested, E and Pollock, KM and Rajeswaran, T and Ramasamy, MN and Rhead, S and Robinson, H and Robinson, N and Sanders, H and Serrano, S and Tipton, T and Waters, A and Zacharopoulou, P and Barnes, E and Dunachie, S and Goulder, P and Klenerman, P and Screaton, GR and Winston, A and Hill, AVS and Gilbert, SC and Carroll, M and Pollard, AJ and Fidler, S and Fox, J and Lambe, T and Frater, J},
             url = {https://doi.org/10.1172/jci.insight.157031}
}